ClinicalTrials.gg
TerminatedNCT01433991Updated Jun 8, 2021Results posted

A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

A Phase 1/2 interventional study of Golvatinib and Lenvatinib in Advanced Solid Tumors, sponsored by Eisai Inc.. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-08.

Sponsored by Eisai Inc. · Phase 1/2, Interventional, and Treatment

How we know · 5 judgments

Why this study was terminated
Study was terminated by the sponsor early at the end of Phase 1b due to a change in corporate strategy.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, open-label, Phase 1b/2 study which will be conducted in two parts: a Phase 1b part comprising a dose escalation and an expansion cohort; and a Phase 2 part which will comprise two cohorts. The purpose of the Phase 1b part is to identify the maximum tolerated dose (MTD) of E7050 and E7080 (lenvatinib) in combination in participants with unresectable advanced or metastatic solid tumors. In the subsequent Phase 1b expansion cohort and Phase 2 cohorts, additional participants with recurrent glioblastoma or unresectable Stage III or Stage IV melanoma and disease progression after prior systemic treatment will be enrolled to confirm the MTD (expansion cohort) and to further explore the clinical activity of E7050 and lenvatinib.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria to be included in this study:

  1. Phase 1b: Unresectable advanced or solid tumors.
  2. Phase 1b expansion cohort and Phase 2: Histological confirmed diagnosis of glioblastoma (expansion cohort and Cohort 1) or melanoma (expansion cohort and Cohort 2).

    Phase 1b expansion cohort glioblastoma participants, Phase 2 Cohort 1:

  3. No evidence of active central nervous systems (CNS) hemorrhage on baseline scans other than in those participants with recurrent glioblastoma who are stable Grade 1.
  4. Participants having first or second recurrence documented by magnetic resonance imaging (MRI), following primary management with surgical resection or , radiotherapy and up to two prior systemic treatments.
  5. If participants is on , they must be on a stable dose for 1 week prior to first dose of study drug.
  6. defined as bidimensionally contrast enhancing lesions with clearly defined margins by computerized tomography (CT) or MRI scan, with a minimal diameter of 1 cm, and visible on two axial slices which are preferably at most 5 millimeter (mm) apart with 0 mm skip.

    Phase 1b expansion cohort melanoma participants, Phase 2 Cohort 2:

  7. Radiographic/ photographic evidence of disease progression according to (RECIST 1.1) (Appendix 3) after no more than two prior systemic regimens for unresectable Stage III or Stage IV disease.
  8. American Joint Committee on Cancer (AJCC) unresectable Stage III or Stage IV melanoma.
  9. Measurable disease meeting the following criteria:

    1. At least one lesion of greater than or equal to 1.0 cm in the longest diameter for a non-lymph node or greater than or equal to 1.5 centimeter (cm) in the short-axis diameter for a lymph node which is serially measurable according to RECIST 1.1 using CT/MRI or photography. If there is only one target lesion and it is a non-lymph node, it should have a longest diameter of greater than or equal to 1.5 cm.
    2. Lesions that have had external beam radiotherapy or loco-regional therapies such as radio frequency ablation must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion.

    All participants:

  10. (ECOG) performance status of 0 or 1.
  11. Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP less than or equal to 150/90 millimeter of mercury (mmHg) at screening and no change in antihypertensive medications within 1 week before the Screening Visit.
  12. Adequate renal function as evidenced by serum creatinine less than or equal to 2.0 milligrams per deciliter (mg/dL) or calculated greater than or equal to 40 milliliters per minute (mL/min) per the Cockcroft and Gault formula (see Appendix 5).
  13. Adequate bone marrow function:

    • greater than or equal to 1500/mm3 (greater than or equal to 1.5 x 10\^3/uL);
    • greater than or equal to 100,000/mm3 (greater than or equal to 100 x 10\^9/L);
    • greater than or equal to 9.0 g/dL. 14.Adequate blood coagulation function, as evidenced by an (INR) less than or equal to 1.5.
  14. Adequate liver function:

    • less than or equal to 1.5 x the (ULN) except for unconjugated hyperbilirubinemia of Gilbert's syndrome;
    • ALP, , and AST less than or equal to 3 x ULN (less than or equal to 5 x ULN if participant has liver metastases).
  15. Males or females age greater than or equal to 18 years at the time of .
  16. All females must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of beta-human chorionic gonadotropin [B-hCG] at the Screening and Baseline Visit (a separate Baseline assessment is not required if a negative Screening pregnancy test was obtained within 72 hours before the first dose of study drug). Females of , if not practising total abstinence or having a vasectomized partner with confirmed azoospermia, must agree to use two highly effective methods of : e.g., 1) an intrauterine device (IUD) or intrauterine system (IUS); 2) a barrier method such as a condom or occlusive cup (diaphragm or cervical/vault caps) + spermicide (foam, gel, cream, etc.); 3) oral, injected, or implanted hormonal contraceptives throughout the entire study period and for 30 days after study drug discontinuation. Use of a double-barrier method (i.e., use at the same time of a condom + occlusive cup [diaphragm or cervical/vault caps] + spermicide [foam, gel, cream, etc.]) is accepted as two highly effective methods of contraception. The only participants who will be exempt from this requirement are women (defined as women who have been amenorrheic for at least 12 consecutive months, in the appropriate age group, without other known or suspected primary cause) or participants who have been sterilized surgically or who are otherwise proven sterile (i.e., bilateral tubal ligation with surgery at least 1 month prior to dosing, total hysterectomy, or bilateral oophorectomy with surgery at least 1 month prior to dosing). All women who are of and who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks prior to dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation.
  17. Male participants who are partners of women of childbearing potential must use a condom + spermicide and their female partners, if of childbearing potential, must use a highly effective method of contraception (see methods described in Inclusion Criterion #18) beginning at least 1 menstrual cycle prior to starting study drug, throughout the entire study period, and for 30 days after the last dose of study drug, unless the male participants are totally abstinent sexually or have undergone a successful vasectomy with confirmed azoospermia or unless the female partners have been sterilized surgically or are otherwise proven sterile (see Inclusion Criterion #16).
  18. Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol.

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following criteria will be excluded from this study:

  1. Phase 1b Dose Escalation: Participants who discontinued prior TK inhibitor (including VEGFR and c-Met receptor targeted therapy) due to toxicity will be ineligible.
  2. Phase 1b Dose Escalation (3+3 portion) participants with primary CNS tumors
  3. Phase 1b Dose Escalation participants, melanoma participants in expansion cohort and Phase 2 Cohort 2: Participants with untreated or unstable to the central nervous system (CNS) are excluded. participants who have completed local therapy and have discontinued the use of for this indication at least 4 weeks prior to commencing treatment and have remained asymptomatic for at least 4 weeks prior to commencing treatment are eligible.
  4. Phase 2: Prior exposure to VEGF-targeted treatment or c-Met or hepatocyte growth factor (HGF) targeted treatment.
  5. Phase 2: Active (except for glioblastoma (Cohort 1) or unresectable Stage III or Stage IV melanoma (Cohort 2); or melanoma in situ, basal or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix) within the past 24 months.

    Phase 1b expansion cohort glioblastoma participants and Phase 2 Cohort 1:

  6. More than two recurrences of glioblastoma.
  7. Prior bevacizumab treatment.
  8. Surgical resection of brain tumor within 4 weeks, or prior stereotactic within 2 weeks of Screening visit.
  9. Prior radiotherapy within 12 weeks unless there is a new area of enhancement consistent with recurrent tumor outside of the radiation field (beyond the high dose region or 80% isodose line), or there is biopsy-proven unequivocal viable tumor on histopathology sampling (e.g., "solid" tumor areas (i.e. greater than 70% tumor cell nuclei in areas), high or progressive increase in MIB-1 proliferation index compared to prior biopsy, or evidence for histological progression or increased anaplasia in the tumor).
  10. Participants who have received enzyme-inducing anti epileptic agents within 14 days before the first dose of study drug (e.g., carbamazepine, phenytoin, phenobarbital, primidone, or oxcarbazepine).

    Phase 1b expansion cohort participants with melanoma and Phase 2 Cohort 2:

  11. More than two prior systemic regimens for unresectable Stage III or Stage IV disease.

    All participants

  12. Prior exposure to E7050 or lenvatinib.
  13. Melanoma of intraocular origin.
  14. participants who have received any anticancer treatment within 21 days (6 weeks for nitrosureas Cohort 1) or any agent within 30 days prior to the first dose of study drug or who have not recovered from any acute toxicity related to previous anticancer treatment.
  15. Major surgery within 3 weeks prior to the first dose of study drug.
  16. Participants having greater than 1+ proteinuria on urinalysis will undergo 24-hour urine collection for quantitative assessment of proteinuria. Participants with urine protein greater than or equal to 1 g/24-hour will be ineligible.
  17. Inability to take oral medication, gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of E7050 or lenvatinib.
  18. Significant cardiovascular impairment: history of congestive heart failure greater than (NYHA) Class II, unstable angina, myocardial infarction or stroke within 6 months of the first dose of study drug; or cardiac arrhythmia requiring medical treatment.
  19. Prolongation of to greater than 480 msec.
  20. Bleeding disorder or thrombotic disorder requiring anticoagulant therapy, such as warfarin, or similar agents requiring therapeutic monitoring (treatment with low molecular weight heparin [LMWH] is allowed).
  21. Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug.
  22. Active infection (any infection requiring antibiotics).
  23. Known intolerance or known to any of the study drugs (or any of the ).
  24. Any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial.
  25. Females who are pregnant or breastfeeding.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Phase 1B

    Participants with unresectable advanced or metastatic solid tumors will receive E7050 in combination with lenvatinib to identify a Maximum Tolerated Dose. Dose escalation will begin at low doses of both E7050 and lenvatinib, and then gradually increase in future cohorts until a recommended combination dose is identified. A dose of E7050 and lenvatinib to be used in combination in Phase 2 will be recommended (RP2 dose). Participants will continue on treatment until disease progression, development of unacceptable toxicity, or withdrawal of consent.

    Drug: Golvatinib · Drug: Lenvatinib

  • Experimental
    Phase 2 Cohort 1 Arm A:

    Participants with recurrent glioblastoma (bevacizumab-naïve) will receive E7050 and lenvatinib at the RP2 dose.

    Drug: Golvatinib · Drug: Lenvatinib

  • Experimental
    Phase 2 Cohort 1 Arm B:

    Participants with recurrent glioblastoma (bevacizumab-naïve) will receive single agent lenvatinib 24 mg/day (1\*4 mg capsule + 2\*10 mg capsule) and at time of progression, E7050 add-on therapy at the RP2 dose (in combination with lenvatinib at dose of either the RP2 dose or the most recent dose of single agent lenvatinib, whichever is the lowest).

    Drug: Golvatinib · Drug: Lenvatinib

  • Experimental
    Phase 2 Cohort 2 Arm C:

    Participants with unresectable Stage III or Stage IV melanoma and disease progression after prior systemic treatment will receive E7050 and lenvatinib at the RP2 dose.

    Drug: Golvatinib · Drug: Lenvatinib

  • Experimental
    Phase 2 Cohort 2 Arm D:

    Participants with unresectable Stage III or Stage IV melanoma and disease progression after prior systemic treatment will receive single agent E7050 400 mg/day.

    Drug: Golvatinib

Interventions

  • Participants will receive E7050 50 mg and/or 100 mg tablets. E7050 will be administered orally once daily, in 28-day cycles.

    Also known as: E7050

  • Participants will receive lenvatinib 1 mg and/or 4 mg and/or 10 mg capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.

    Also known as: E7080

  • Participants will receive lenvatinib 24 mg (1\*4 mg capsule + 2\*10 mg capsule) capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.

    Also known as: E7080

06

What researchers measure

Primary outcomes

  1. Phase 1b: Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT)- Combination Treatment

    DLT was defined as toxicity related to the combination therapy and was graded according to Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). Hematological DLTs were Grade 4 neutropenia for greater than or equal to (\>=) 7 days or Grade 3 neutropenia with fever (greater than \[\>\] 38.5 degree Celsius (°C) in axilla), Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding or lasting \>7 days and decrease of hemoglobin of Grade 4. Non-hematological DLTS were Grade 3 fatigue, or a 2 point decline in Eastern Cooperative Oncology Group (ECOG) performance status must persist for \>7days, Nausea, vomiting or diarrhea must persist at Grade 3 or 4 despite maximal medical therapy, Grade 4 hypertension or Grade 3 hypertension not able to be controlled by medication and any Grade 3 or higher non-hematological laboratory abnormalities that require hospitalization.

    Time frame: Cycle 1 (Cycle length= 28 days)

  2. Phase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Golvatinib in Combination With Lenvatinib

    The MTD was defined as the highest dose level at which no more than 1/6 participants experienced a DLTs, with the next higher dose having at least 0 of 3 or 1 of 6 participants experiencing DLTs. MTD was determined by summarizing the number and percentage of participants with DLTs for the first cycle, by study dosing schedule, initial dosing level and overall for the dose escalation part. The RP2D of golvatinib in Combination with lenvatinib was MTD determined by Dose Escalation Committee (DEC) based on safety, PK and clinical data. DLT was defined as toxicity related to the combination therapy and was graded according to CTCAE v4.0.

    Time frame: Cycle 1 (Cycle length= 28 days)

  3. Phase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Lenvatinib in Combination With Golvatinib

    The MTD was defined as the highest dose level at which no more than 1/6 participants experienced a DLTs, with the next higher dose having at least 0 of 3 or 1 of 6 participants experiencing DLTs. MTD was determined by summarizing the number and percentage of participants with DLTs for the first cycle, by study dosing schedule, initial dosing level and overall for the dose escalation part. The RP2D of lenvatinib in Combination with golvatinib was MTD determined by DEC based on safety, PK and clinical data. DLT was defined as toxicity related to the combination therapy and was graded according to CTCAE v4.0.

    Time frame: Cycle 1 (Cycle length= 28 days)

Secondary outcomes

  1. Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Laboratory Values- Combination Treatment

    Time frame: From baseline up to approximately 5 years 5 months

  2. Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Vital Signs Values- Combination Treatment

    Time frame: From baseline up to approximately 5 years 5 months

  3. Phase 1b: Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Values- Combination Treatment

    Time frame: From baseline up to approximately 5 years 5 months

  4. Phase 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)- Combination Treatment

    Time frame: From baseline up to approximately up to 5 years 5 months

  5. Phase 1b: Cmax; Maximum Observed Plasma Concentration for Golvatinib When Administered as a Single Agent at Day -7

    Time frame: Day -7: 0-24 hours post-dose

  6. Phase 1b: Cmax; Maximum Observed Plasma Concentration for Lenvatinib When Administered as a Single Agent at Day -8

    Time frame: Day -8: 0-24 hours post-dose

  7. Phase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Golvatinib When Administered as a Single Agent at Day -7

    Time frame: Day -7: 0-24 hours post-dose

  8. Phase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Lenvatinib When Administered as a Single Agent at Day -8

    Time frame: Day -8: 0-24 hours post-dose

  9. Phase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Golvatinib When Administered as Single Agent at Day -7

    Time frame: Day -7: 0-24 hours post-dose

  10. Phase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Lenvatinib When Administered as Single Agent at Day -8

    Time frame: Day -8: 0-24 hours post-dose

  11. Phase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Golvatinib When Administered as Single Agent at Day -7

    Time frame: Day -7: 0-24 hours post-dose

  12. Phase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Lenvatinib When Administered as Single Agent at Day -8

    Time frame: Day -8: 0-24 hours post-dose

  13. Phase 1b: AUC∞; Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for Golvatinib When Administered as Single Agent at Day -7

    Time frame: Day -7: 0-24 hours post-dose

  14. Phase 1b: AUC∞; Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for Lenvatinib When Administered as Single Agent at Day -8

    Time frame: Day -8: 0-24 hours post-dose

  15. Phase 1b: t1/2; Terminal Elimination Half-life for Golvatinib When Administered as Single Agent at Day -7

    Time frame: Day-7: 0-24 hours post-dose

  16. Phase 1b: t1/2; Terminal Elimination Half-life for Lenvatinib When Administered as Single Agent at Day -8

    Time frame: Day -8: 0-24 hours post-dose

  17. Phase 1b: CL/F; Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration for Golvatinib When Administered as Single Agent at Day -7

    Time frame: Day -7: 0-24 hours post-dose

  18. Phase 1b: CL/F; Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration for Lenvatinib When Administered as Single Agent at Day -8

    Time frame: Day -8: 0-24 hours post-dose

  19. Phase 1b: Vz/F; Apparent Volume of Distribution at Terminal Phase for Golvatinib When Administered as Single Agent at Day -7

    Time frame: Day -7: 0-24 hours post-dose

  20. Phase 1b: Vz/F; Apparent Volume of Distribution at Terminal Phase for Lenvatinib When Administered as Single Agent at Day -8

    Time frame: Day -8: 0-24 hours post dose

  21. Phase 1b: Cmax; Maximum Observed Plasma Concentration for Golvatinib and Lenvatinib When Administered in Combination Treatment as Single Dose on Day 1 Cycle 1

    Time frame: Cycle 1 Day 1: 0-24 hours post-dose (cycle length is 28 days)

  22. Phase 1b: Cmax; Maximum Observed Plasma Concentration for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2

    Time frame: Cycle 2 Day 1: 0-24 hours post-dose (cycle length is 28 days)

  23. Phase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Golvatinib and Lenvatinib When Administered in Combination Treatment as Single Dose on Day 1 Cycle 1

    Time frame: Cycle 1 Day 1: 0-24 hours post-dose (cycle length is 28 days)

  24. Phase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2

    Time frame: Cycle 2 Day 1: 0-24 hours post-dose (cycle length is 28 days)

  25. Phase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Golvatinib and Lenvatinib When Administered in Combination Treatment as Single Dose on Day 1 Cycle 1

    Time frame: Cycle 1 Day 1: 0-24 hours post-dose (cycle length is 28 days)

  26. Phase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2

    Time frame: Cycle 2 Day 1: 0-24 hours post-dose (cycle length is 28 days)

  27. Phase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Golvatinib and Lenvatinib When Administered in Combination Treatment as Single Dose on Day 1 Cycle 1

    Time frame: Cycle 1 Day 1: 0-24 hours post-dose (cycle length is 28 days)

  28. Phase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2

    Time frame: Cycle 2 Day 1: 0-24 hours post-dose (cycle length is 28 days)

  29. Phase 1b: CLss/F; Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2

    Time frame: Cycle 2 Day 1: 0-24 hours post-dose (cycle length is 28 days)

  30. Phase 1b: Rac(AUC); Accumulation Ratio Based on AUC Calculated as AUC24 at Steady State/AUC24 for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2

    Time frame: Cycle 2 Day 1: 0-24 hours post-dose (cycle length is 28 days)

  31. Phase 1b: Rac(Cmax); Accumulation Ratio Based on Cmax Calculated as Cmax at Steady State/Cmax for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2

    Time frame: Cycle 2 Day 1: 0-24 hours post-dose (cycle length is 28 days)

  32. Phase 1b: Objective Response Rate (ORR); Combination Treatment

    ORR was assessed by the investigator based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. ORR was defined as the percentage of participants with confirmed best overall response (BOR) of complete response (CR) or partial response (PR). CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<)10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From the date of the first dose of study drug to the date of the first documentation of disease progression or death, whichever occurred first (approximately up to 5 years 5 months)

07

Results

Posted Jun 8, 2021
Limitations and caveats
The study was terminated by the sponsor at the end of Phase 1b due to a change in corporate strategy, hence Phase 2 was not carried out.

Participant flow

Participants took part in the study at 2 investigative sites in the United States from 13 October 2011 to 01 March 2017.

Pretreatment Phase (Single Agent Run-in)
Participant flow — Pretreatment Phase (Single Agent Run-in)
MilestoneCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Started53148
Completed33148
Not completed2000
Withdrew: Did not enter into treatment phase2000
Treatment Phase (Combination Agent)
Participant flow — Treatment Phase (Combination Agent)
MilestoneCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Started33148
Completed1282
Not completed2166
Withdrew: Adverse event1031
Withdrew: Lost to follow-up0001
Withdrew: Participant choice0001
Withdrew: Clinical progression0123
Withdrew: Progressive disease1000
Withdrew: Terminated by sponsor0010

Outcome measures

PrimaryPhase 1b: Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT)- Combination Treatment

DLT was defined as toxicity related to the combination therapy and was graded according to Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). Hematological DLTs were Grade 4 neutropenia for greater than or equal to (\>=) 7 days or Grade 3 neutropenia with fever (greater than \[\>\] 38.5 degree Celsius (°C) in axilla), Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding or lasting \>7 days and decrease of hemoglobin of Grade 4. Non-hematological DLTS were Grade 3 fatigue, or a 2 point decline in Eastern Cooperative Oncology Group (ECOG) performance status must persist for \>7days, Nausea, vomiting or diarrhea must persist at Grade 3 or 4 despite maximal medical therapy, Grade 4 hypertension or Grade 3 hypertension not able to be controlled by medication and any Grade 3 or higher non-hematological laboratory abnormalities that require hospitalization.

Time frame:
Cycle 1 (Cycle length= 28 days)
Reported as:
Count of participants · Participants
Phase 1b: Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT)- Combination Treatment
ParticipantsCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Phase 1b: Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT)- Combination Treatment0042
PrimaryPhase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Golvatinib in Combination With Lenvatinib

The MTD was defined as the highest dose level at which no more than 1/6 participants experienced a DLTs, with the next higher dose having at least 0 of 3 or 1 of 6 participants experiencing DLTs. MTD was determined by summarizing the number and percentage of participants with DLTs for the first cycle, by study dosing schedule, initial dosing level and overall for the dose escalation part. The RP2D of golvatinib in Combination with lenvatinib was MTD determined by Dose Escalation Committee (DEC) based on safety, PK and clinical data. DLT was defined as toxicity related to the combination therapy and was graded according to CTCAE v4.0.

Time frame:
Cycle 1 (Cycle length= 28 days)
Reported as:
Number · milligram per day (mg/day)
Phase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Golvatinib in Combination With Lenvatinib
milligram per day (mg/day)All Cohorts: Golvatinib + Lenvatinib
MTD300.0
RP2D300.0
PrimaryPhase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Lenvatinib in Combination With Golvatinib

The MTD was defined as the highest dose level at which no more than 1/6 participants experienced a DLTs, with the next higher dose having at least 0 of 3 or 1 of 6 participants experiencing DLTs. MTD was determined by summarizing the number and percentage of participants with DLTs for the first cycle, by study dosing schedule, initial dosing level and overall for the dose escalation part. The RP2D of lenvatinib in Combination with golvatinib was MTD determined by DEC based on safety, PK and clinical data. DLT was defined as toxicity related to the combination therapy and was graded according to CTCAE v4.0.

Time frame:
Cycle 1 (Cycle length= 28 days)
Reported as:
Number · mg/day
Phase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Lenvatinib in Combination With Golvatinib
mg/dayAll Cohorts: Lenvatinib + Golvatinib
MTD20.0
RP2D20.0
SecondaryPhase 1b: Number of Participants With Clinically Significant Change From Baseline in Laboratory Values- Combination Treatment
Time frame:
From baseline up to approximately 5 years 5 months
Reported as:
Count of participants · Participants
Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Laboratory Values- Combination Treatment
ParticipantsCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Laboratory Values- Combination Treatment0000
SecondaryPhase 1b: Number of Participants With Clinically Significant Change From Baseline in Vital Signs Values- Combination Treatment
Time frame:
From baseline up to approximately 5 years 5 months
Reported as:
Count of participants · Participants
Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Vital Signs Values- Combination Treatment
ParticipantsCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Vital Signs Values- Combination Treatment0000
SecondaryPhase 1b: Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Values- Combination Treatment
Time frame:
From baseline up to approximately 5 years 5 months
Reported as:
Count of participants · Participants
Phase 1b: Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Values- Combination Treatment
ParticipantsCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Baseline and post-baseline data33138
At least 1 post-baseline increase of greater than (>) 30 millisecond (msec)2014
At least 1 post-baseline increase of > 60 msec1000
At least 1 post-baseline value of > 450 msec2284
At least 1 post-baseline value of > 480 msec1041
At least 1 post-baseline value of > 500 msec1010
SecondaryPhase 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)- Combination Treatment
Time frame:
From baseline up to approximately up to 5 years 5 months
Reported as:
Count of participants · Participants
Phase 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)- Combination Treatment
ParticipantsCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
TEAEs33148
SAEs2183
SecondaryPhase 1b: Cmax; Maximum Observed Plasma Concentration for Golvatinib When Administered as a Single Agent at Day -7
Time frame:
Day -7: 0-24 hours post-dose
Reported as:
Mean · nanograms per milliliter (ng/mL)
Phase 1b: Cmax; Maximum Observed Plasma Concentration for Golvatinib When Administered as a Single Agent at Day -7
nanograms per milliliter (ng/mL)Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Phase 1b: Cmax; Maximum Observed Plasma Concentration for Golvatinib When Administered as a Single Agent at Day -72160 ± 8481710 ± 14103020 ± 21303930 ± 1800
SecondaryPhase 1b: Cmax; Maximum Observed Plasma Concentration for Lenvatinib When Administered as a Single Agent at Day -8
Time frame:
Day -8: 0-24 hours post-dose
Reported as:
Mean · ng/mL
Phase 1b: Cmax; Maximum Observed Plasma Concentration for Lenvatinib When Administered as a Single Agent at Day -8
ng/mLCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Phase 1b: Cmax; Maximum Observed Plasma Concentration for Lenvatinib When Administered as a Single Agent at Day -8174 ± 88.0393 ± 75.0297 ± 159388 ± 250
SecondaryPhase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Golvatinib When Administered as a Single Agent at Day -7
Time frame:
Day -7: 0-24 hours post-dose
Reported as:
Median · hours
Phase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Golvatinib When Administered as a Single Agent at Day -7
hoursCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Phase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Golvatinib When Administered as a Single Agent at Day -72.00 (1.43 to 11.6)4.00 (3.02 to 4.08)2.54 (1.95 to 4.08)2.54 (1.98 to 7.92)
SecondaryPhase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Lenvatinib When Administered as a Single Agent at Day -8
Time frame:
Day -8: 0-24 hours post-dose
Reported as:
Median · hours
Phase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Lenvatinib When Administered as a Single Agent at Day -8
hoursCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Phase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Lenvatinib When Administered as a Single Agent at Day -83.00 (1.00 to 3.08)2.00 (2.00 to 2.92)3.01 (1.93 to 8.00)3.00 (1.00 to 23.50)
SecondaryPhase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Golvatinib When Administered as Single Agent at Day -7
Time frame:
Day -7: 0-24 hours post-dose
Reported as:
Mean · nanogram*hour per milliliter(ng*h/mL)
Phase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Golvatinib When Administered as Single Agent at Day -7
nanogram*hour per milliliter(ng*h/mL)Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Phase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Golvatinib When Administered as Single Agent at Day -725600 ± 672019300 ± 1400034400 ± 2560050000 ± 27900
SecondaryPhase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Lenvatinib When Administered as Single Agent at Day -8
Time frame:
Day -8: 0-24 hours post-dose
Reported as:
Mean · ng*h/mL
Phase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Lenvatinib When Administered as Single Agent at Day -8
ng*h/mLCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Phase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Lenvatinib When Administered as Single Agent at Day -81540 ± 5812690 ± 75.72620 ± 11603200 ± 2210
SecondaryPhase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Golvatinib When Administered as Single Agent at Day -7
Time frame:
Day -7: 0-24 hours post-dose
Reported as:
Mean · ng*h/mL
Phase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Golvatinib When Administered as Single Agent at Day -7
ng*h/mLCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Phase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Golvatinib When Administered as Single Agent at Day -726500 ± 638034700 ± 2790038000 ± 2540064000 ± 33000
SecondaryPhase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Lenvatinib When Administered as Single Agent at Day -8
Time frame:
Day -8: 0-24 hours post-dose
Reported as:
Mean · ng*h/mL
Phase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Lenvatinib When Administered as Single Agent at Day -8
ng*h/mLCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Phase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Lenvatinib When Administered as Single Agent at Day -81800 ± 6973030 ± 2543030 ± 12603780 ± 2630
SecondaryPhase 1b: AUC∞; Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for Golvatinib When Administered as Single Agent at Day -7
Time frame:
Day -7: 0-24 hours post-dose
Reported as:
Mean · ng*h/mL
Phase 1b: AUC∞; Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for Golvatinib When Administered as Single Agent at Day -7
ng*h/mLCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Phase 1b: AUC∞; Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for Golvatinib When Administered as Single Agent at Day -7—58300 ± 2350051200 ± NA—
SecondaryPhase 1b: AUC∞; Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for Lenvatinib When Administered as Single Agent at Day -8
Time frame:
Day -8: 0-24 hours post-dose
Reported as:
Mean · ng*h/mL
Phase 1b: AUC∞; Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for Lenvatinib When Administered as Single Agent at Day -8
ng*h/mLCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Phase 1b: AUC∞; Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for Lenvatinib When Administered as Single Agent at Day -81890 ± 6933060 ± 2502930 ± 13603910 ± 2680
SecondaryPhase 1b: t1/2; Terminal Elimination Half-life for Golvatinib When Administered as Single Agent at Day -7
Time frame:
Day-7: 0-24 hours post-dose
Reported as:
Mean · hours
Phase 1b: t1/2; Terminal Elimination Half-life for Golvatinib When Administered as Single Agent at Day -7
hoursCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Phase 1b: t1/2; Terminal Elimination Half-life for Golvatinib When Administered as Single Agent at Day -7—34.6 ± 1.7730.7 ± NA57.0 ± 1.70
SecondaryPhase 1b: t1/2; Terminal Elimination Half-life for Lenvatinib When Administered as Single Agent at Day -8
Time frame:
Day -8: 0-24 hours post-dose
Reported as:
Mean · hours
Phase 1b: t1/2; Terminal Elimination Half-life for Lenvatinib When Administered as Single Agent at Day -8
hoursCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Phase 1b: t1/2; Terminal Elimination Half-life for Lenvatinib When Administered as Single Agent at Day -811.2 ± 3.2714.6 ± 6.6912.0 ± 5.4914.4 ± 6.86
SecondaryPhase 1b: CL/F; Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration for Golvatinib When Administered as Single Agent at Day -7
Time frame:
Day -7: 0-24 hours post-dose
Reported as:
Mean · liter per hour (L/h)
Phase 1b: CL/F; Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration for Golvatinib When Administered as Single Agent at Day -7
liter per hour (L/h)Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Phase 1b: CL/F; Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration for Golvatinib When Administered as Single Agent at Day -7—3.74 ± 1.515.87 ± NA—
SecondaryPhase 1b: CL/F; Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration for Lenvatinib When Administered as Single Agent at Day -8
Time frame:
Day -8: 0-24 hours post-dose
Reported as:
Mean · liter per hour (L/h)
Phase 1b: CL/F; Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration for Lenvatinib When Administered as Single Agent at Day -8
liter per hour (L/h)Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Phase 1b: CL/F; Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration for Lenvatinib When Administered as Single Agent at Day -87.01 ± 2.316.57 ± 0.5568.63 ± 5.337.23 ± 4.25
SecondaryPhase 1b: Vz/F; Apparent Volume of Distribution at Terminal Phase for Golvatinib When Administered as Single Agent at Day -7
Time frame:
Day -7: 0-24 hours post-dose
Reported as:
Mean · liter (L)
Phase 1b: Vz/F; Apparent Volume of Distribution at Terminal Phase for Golvatinib When Administered as Single Agent at Day -7
liter (L)Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Phase 1b: Vz/F; Apparent Volume of Distribution at Terminal Phase for Golvatinib When Administered as Single Agent at Day -7—188 ± 84.9260 ± NA—
SecondaryPhase 1b: Vz/F; Apparent Volume of Distribution at Terminal Phase for Lenvatinib When Administered as Single Agent at Day -8
Time frame:
Day -8: 0-24 hours post dose
Reported as:
Mean · liter (L)
Phase 1b: Vz/F; Apparent Volume of Distribution at Terminal Phase for Lenvatinib When Administered as Single Agent at Day -8
liter (L)Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Phase 1b: Vz/F; Apparent Volume of Distribution at Terminal Phase for Lenvatinib When Administered as Single Agent at Day -8112 ± 53.4135 ± 55.1182 ± 209137 ± 87.5
SecondaryPhase 1b: Cmax; Maximum Observed Plasma Concentration for Golvatinib and Lenvatinib When Administered in Combination Treatment as Single Dose on Day 1 Cycle 1
Time frame:
Cycle 1 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Reported as:
Mean · ng/mL
Phase 1b: Cmax; Maximum Observed Plasma Concentration for Golvatinib and Lenvatinib When Administered in Combination Treatment as Single Dose on Day 1 Cycle 1
ng/mLCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Golvatinib: Cycle 1 Day 12890 ± 10801990 ± 14703050 ± 10304820 ± 1510
Lenvatinib: Cycle 1 Day 1182 ± 137315 ± 35.4258 ± 148251 ± 144
SecondaryPhase 1b: Cmax; Maximum Observed Plasma Concentration for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2
Time frame:
Cycle 2 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Reported as:
Mean · ng/mL
Phase 1b: Cmax; Maximum Observed Plasma Concentration for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2
ng/mLCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Golvatinib: Cycle 2 Day 13540 ± NA2750 ± 8703570 ± 13506920 ± 4130
Lenvatinib: Cycle 2 Day 166.3 ± NA356 ± 76.4245 ± 110408 ± 250
SecondaryPhase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Golvatinib and Lenvatinib When Administered in Combination Treatment as Single Dose on Day 1 Cycle 1
Time frame:
Cycle 1 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Reported as:
Median · hours
Phase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Golvatinib and Lenvatinib When Administered in Combination Treatment as Single Dose on Day 1 Cycle 1
hoursCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Golvatinib: Cycle 1 Day 13.02 (2.12 to 4.02)4.00 (2.03 to 4.08)3.52 (1.98 to 8.05)3.00 (0.98 to 4.13)
Lenvatinib: Cycle 1 Day 13.02 (2.12 to 4.02)2.02 (2.00 to 2.03)3.95 (1.98 to 4.03)3.98 (2.00 to 4.13)
SecondaryPhase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2
Time frame:
Cycle 2 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Reported as:
Median · hours
Phase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2
hoursCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Golvatinib: Cycle 2 Day 18.05 (8.05 to 8.05)2.00 (1.00 to 3.00)2.97 (1.02 to 3.97)3.53 (3.00 to 7.92)
Lenvatinib: Cycle 2 Day 110.55 (10.55 to 10.55)3.00 (2.00 to 4.00)3.90 (2.03 to 3.97)3.53 (2.00 to 7.92)
SecondaryPhase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Golvatinib and Lenvatinib When Administered in Combination Treatment as Single Dose on Day 1 Cycle 1
Time frame:
Cycle 1 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Reported as:
Mean · ng*h/mL
Phase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Golvatinib and Lenvatinib When Administered in Combination Treatment as Single Dose on Day 1 Cycle 1
ng*h/mLCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Golvatinib: Cycle 1 Day 133800 ± 427022100 ± 1590038700 ± 2170060400 ± 26200
Lenvatinib: Cycle 1 Day 11460 ± 9222370 ± 35.42290 ± 12502390 ± 1710
SecondaryPhase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2
Time frame:
Cycle 2 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Reported as:
Mean · ng*h/mL
Phase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2
ng*h/mLCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Golvatinib: Cycle 2 Day 168700 ± NA45000 ± 2970057100 ± 25300138000 ± 98900
Lenvatinib: Cycle 2 Day 11120 ± NA3060 ± 2472380 ± 14304320 ± 3860
SecondaryPhase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Golvatinib and Lenvatinib When Administered in Combination Treatment as Single Dose on Day 1 Cycle 1
Time frame:
Cycle 1 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Reported as:
Mean · ng*h/mL
Phase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Golvatinib and Lenvatinib When Administered in Combination Treatment as Single Dose on Day 1 Cycle 1
ng*h/mLCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Golvatinib: Cycle 1 Day 134000 ± 429022200 ± 1590039800 ± 2180060800 ± 26700
Lenvatinib: Cycle 1 Day 11470 ± 9212370 ± 42.42400 ± 12702400 ± 1730
SecondaryPhase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2
Time frame:
Cycle 2 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Reported as:
Mean · ng*h/mL
Phase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2
ng*h/mLCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Golvatinib: Cycle 2 Day 168700 ± NA45200 ± 2950057100 ± 25300138000 ± 98700
Lenvatinib: Cycle 2 Day 11120 ± NA3060 ± 2552380 ± 14304330 ± 3850
SecondaryPhase 1b: CLss/F; Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2
Time frame:
Cycle 2 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Reported as:
Mean · liter per hour (L/h)
Phase 1b: CLss/F; Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2
liter per hour (L/h)Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Golvatinib: Cycle 2 Day 1—5.69 ± 3.76—3.49 ± 1.81
Lenvatinib: Cycle 2 Day 1—6.58 ± 0.54—7.96 ± 5.72
SecondaryPhase 1b: Rac(AUC); Accumulation Ratio Based on AUC Calculated as AUC24 at Steady State/AUC24 for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2
Time frame:
Cycle 2 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Reported as:
Mean · ratio
Phase 1b: Rac(AUC); Accumulation Ratio Based on AUC Calculated as AUC24 at Steady State/AUC24 for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2
ratioCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Golvatinib: Cycle 2 Day 12.35 ± NA3.96 ± 2.141.90 ± 0.9052.10 ± 0.254
Lenvatinib: Cycle 2 Day 11.88 ± NA1.29 ± 0.1270.928 ± 0.2951.61 ± 0.670
SecondaryPhase 1b: Rac(Cmax); Accumulation Ratio Based on Cmax Calculated as Cmax at Steady State/Cmax for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2
Time frame:
Cycle 2 Day 1: 0-24 hours post-dose (cycle length is 28 days)
Reported as:
Mean · ratio
Phase 1b: Rac(Cmax); Accumulation Ratio Based on Cmax Calculated as Cmax at Steady State/Cmax for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2
ratioCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Golvatinib: Cycle 2 Day 12.11 ± NA3.16 ± 2.241.30 ± 0.4811.49 ± 0.319
Lenvatinib: Cycle 2 Day 11.44 ± NA1.13 ± 0.1201.17 ± 0.5561.63 ± 1.27
SecondaryPhase 1b: Objective Response Rate (ORR); Combination Treatment

ORR was assessed by the investigator based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. ORR was defined as the percentage of participants with confirmed best overall response (BOR) of complete response (CR) or partial response (PR). CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<)10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From the date of the first dose of study drug to the date of the first documentation of disease progression or death, whichever occurred first (approximately up to 5 years 5 months)
Reported as:
Number · percentage of participants
Phase 1b: Objective Response Rate (ORR); Combination Treatment
percentage of participantsCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
Phase 1b: Objective Response Rate (ORR); Combination Treatment0 (NA to NA)0 (NA to NA)28.6 (8.4 to 58.1)12.5 (0.3 to 52.7)

Adverse events

Collected over From baseline up to approximately 5 years 5 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mg1/3 (33.3%)2/3 (66.7%)3/3 (100%)
Cohort 2: Lenvatinib 20 mg + Golvatinib 200 mg1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Cohort 3: Lenvatinib 20 mg + Golvatinib 300 mg0/14 (0%)8/14 (57.1%)13/14 (92.9%)
Cohort 4: Lenvatinib 20 mg + Golvatinib 400 mg3/8 (37.5%)3/8 (37.5%)8/8 (100%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
PyrexiaGeneral disorders1/30/30/140/8
Lung InfectionInfections and infestations0/31/30/140/8
Back PainMusculoskeletal and connective tissue disorders1/30/31/140/8
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders1/30/30/141/8
Electrocardiogram Qt ProlongedInvestigations1/30/30/140/8
Malignant Pleural EffusionNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/30/30/140/8
Abdominal PainGastrointestinal disorders0/30/32/140/8
DiarrhoeaGastrointestinal disorders0/30/30/141/8
BacteraemiaInfections and infestations0/30/30/141/8
Musculoskeletal Chest PainMusculoskeletal and connective tissue disorders0/30/30/141/8
Most frequent other events
Showing 10 of 188
Most frequent other events
EventCohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mg
VomitingGastrointestinal disorders3/32/39/146/8
FatigueGeneral disorders2/33/311/145/8
Decreased AppetiteMetabolism and nutrition disorders3/32/310/145/8
DysphoniaRespiratory, thoracic and mediastinal disorders1/33/33/143/8
NauseaGastrointestinal disorders3/33/37/144/8
DiarrhoeaGastrointestinal disorders1/32/313/145/8
Aspartate Aminotransferase IncreasedInvestigations1/30/310/143/8
Oral PainGastrointestinal disorders0/32/32/140/8
AstheniaGeneral disorders2/30/31/141/8
DehydrationMetabolism and nutrition disorders2/30/37/144/8

Baseline characteristics

The safety analysis set (combination treatment) included all participants who received at least 1 dose of combination treatment and had at least 1 postbaseline safety evaluation.

Age, Continuous
Age, Continuous(years)Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mgTotal
Median58.0 (36 to 66)63.0 (54 to 65)64.5 (41 to 75)56.5 (34 to 73)62.0 (34 to 75)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mgTotal
Female117413
Male227415
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: Lenvatinib 12 mg + Golvatinib 200 mgCohort 2: Lenvatinib 20 mg + Golvatinib 200 mgCohort 3: Lenvatinib 20 mg + Golvatinib 300 mgCohort 4: Lenvatinib 20 mg + Golvatinib 400 mgTotal
White3312826
Asian00101
Other00101
08

Study locations

2 sites
  • Dana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Massachusetts General Hospital / Dana Farber Cancer Institute
    Boston, Massachusetts, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2011 to primary completion in Mar 2015, 41 months.

Results were first posted in Jun 2021, 6 years 2 months after primary completion. A results delay was requested in Apr 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2011
First posted
Sep 14, 2011
StartActual
Oct 13, 2011
Primary completionActual
Mar 18, 2015
CompletionActual
Mar 1, 2017
Results delay requested
Apr 11, 2016
Results first posted
Jun 8, 2021
Last update
Jun 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01433991
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Sep 14, 2011
Start date
Oct 13, 2011
Primary completion
Mar 18, 2015
Completion
Mar 1, 2017
Results posted
Jun 8, 2021
Last update
Jun 8, 2021

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Golvatinib · Lenvatinib

Start the discussion